Glenmark

Glenmark Pharmaceuticals receives tentative ANDA approval for generic version of Epiduo® Gel

  • Posted on: 30 April 2016
  • By: Shalini.Sharma

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Adapalene and Benzoyl Peroxide Gel, 0.1%|2.5%, the generic version of Epiduo® Gel of Galderma Laboratories L.P.

Glenmark Pharmaceuticals Entered Into Agreement With Poland Based Celon for Generic Seretide Accuhaler

  • Posted on: 27 October 2015
  • By: Shalini.Sharma

Glenmark Pharmaceuticals has entered into an agreement with Poland based Celon Pharma to develop and market a generic version of GlaxoSmithKline's Seretide Accuhaler in Europe used for treatment of lung diseases. The fluticasone/salmeterol dry powder inhaler is a combination product for the treatment of chronic obstructive pulmonary disease.

Glenmark’s GBR 830 entered into phase 2 studies in AD and celiac disease in US & Europe

  • Posted on: 8 September 2015
  • By: Shalini.Sharma

Glenmark Pharmaceuticals S.A., GBR 830, a novel monoclonal antibody has completed clinical phase 1 dosing. GBR 830 is an antagonist of OX40, a costimulatory receptor expressed on T cells mediating T cell activation and survival. Glenmark has now completed clinical phase I studies for GBR 830 in the Netherlands.

Glenmark introduce third generation oral anti diabetic agent Teneligliptin priced at Rs. 19.90 per tab

  • Posted on: 29 July 2015
  • By: Shalini.Sharma

In India Glenmark Pharmaceuticals has now introduced its new third generation oral anti diabetic agent Teneligliptin for type-2 diabetes  at an affordable price of Rs. 19.90 per tablet. The first pan India launch of Teneligliptin under two brands: Ziten and Zita Plus took place in Bengaluru. The molecule gliptin comes under the category of DPP-4 inhibitors, which is backed by scientific data as being safe, well tolerated, weight neutral with low risk of hypoglycemia.

Glenmark receive US FDA approval for generic Dovonex cream, 0.005%

  • Posted on: 16 June 2015
  • By: Shalini.Sharma

Glenmark Pharmaceuticals Inc., USA (Glenmark) get final approval by the United States Food & Drug Administration (FDA) for calcipotriene cream, 0.005 per cent, the therapeutic equivalent of Dovonex cream, 0.005 per cent of Leo Pharma A/S.  Glenmark strategy to start to shipping of calcipotriene cream, 0.005 per cent immediately.

Pages